Related Experiment Video
Updated: Mar 30, 2026
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives
Nicoletta Colombo1, Pier Franco Conte2, Sandro Pignata3
1University of Milan Bicocca and European Institute of Oncology, via Ripamonti 435, Milan, Italy.
Abstract:
The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.
Insights
Anti-angiogenic agents, like bevacizumab, show promise in advanced ovarian cancer management. Further research is needed to optimize treatment timing, patient selection, and duration for improved outcomes.
Area of Science:
- Oncology
- Gynecologic Oncology
- Pharmacological Research
Background:
- Advanced ovarian cancer management has seen significant progress.
- Anti-angiogenic agents, particularly bevacizumab, have demonstrated efficacy in clinical trials.
- Key questions persist regarding optimal treatment strategies and patient selection.
Purpose of the Study:
- To review pivotal phase III trials of bevacizumab in advanced ovarian cancer.
- To summarize overall survival data and emerging maintenance strategies.
- To identify and discuss unanswered questions and future research directions.
Main Methods:
- Systematic review of five pivotal phase III trials of bevacizumab.
- Analysis of overall survival data.
- Evaluation of emerging maintenance strategies and re-treatment data.
Main Results:
- Bevacizumab has shown positive results in front-line and recurrent settings for advanced ovarian cancer.
- Final overall survival data from key trials are summarized.
- Emerging data on maintenance strategies and re-exposure are highlighted.
Conclusions:
- Anti-angiogenic therapy represents a significant advancement in ovarian cancer treatment.
- Further research is crucial to address optimal timing, patient selection, and treatment duration.
- Investigating bevacizumab re-exposure and integration into neoadjuvant regimens is warranted.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...